Functional Proteomics Laboratory, Centro de Investigaciones Biológicas, Madrid, Spain.
Proteomics Clin Appl. 2010 Feb;4(2):159-78. doi: 10.1002/prca.200900131. Epub 2010 Jan 14.
Colorectal cancer (CRC) is a widespread disease, whose major genetic changes and mutations have been well characterized in the sporadic form. Much less is known at the protein and proteome level. Still, CRC has been the subject of multiple proteomic studies due to the urgent necessity of finding clinically relevant markers and to elucidate the molecular mechanisms underlying the progression of the disease. These proteomic approaches have been limited by different technical issues, mainly related with sensitivity and reproducibility. However, recent advances in proteomic techniques and MS systems have rekindled the quest for new biomarkers in CRC and an improved molecular characterization. In this review, we will discuss the application of different proteomic approaches to the identification of differentially expressed proteins in CRC. In particular, we will make a critical assessment about the use of 2-D DIGE, MS and protein microarray technologies, in their different formats, to identify up- or downregulated proteins and/or autoantibodies profiles that could be useful for CRC characterization and diagnosis. Despite a wide list of potential biomarkers, it is clear that more scientific efforts and technical advances are still needed to cover the range of low-abundant proteins, which may play a key role in CRC diagnostics and progression.
结直肠癌(CRC)是一种广泛存在的疾病,其在散发性形式中的主要遗传变化和突变已得到很好的描述。在蛋白质和蛋白质组水平上,人们的了解要少得多。尽管如此,由于迫切需要找到临床相关的标志物并阐明疾病进展的分子机制,CRC 仍然是多个蛋白质组学研究的主题。这些蛋白质组学方法受到不同技术问题的限制,主要与灵敏度和重现性有关。然而,蛋白质组学技术和 MS 系统的最新进展重新激发了在 CRC 中寻找新生物标志物和改善分子表征的探索。在这篇综述中,我们将讨论不同蛋白质组学方法在鉴定 CRC 中差异表达蛋白中的应用。特别是,我们将对 2-D DIGE、MS 和蛋白质微阵列技术的应用进行批判性评估,包括其不同形式,以鉴定上调或下调的蛋白质和/或自身抗体谱,这些可能对 CRC 的特征和诊断有用。尽管有大量的潜在生物标志物,但显然还需要更多的科学努力和技术进步来涵盖低丰度蛋白质的范围,这些蛋白质可能在 CRC 的诊断和进展中发挥关键作用。